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Introduction: Differences in the organisation of idiopathic pulmonary fibrosis (IPF) and interstitial lung dis-
eases (ILDs) in the Nordic countries are not well described. Diagnostic setups, treatment modalities and follow-
up plans may vary due to national, cultural and epidemiological features. The aim of the present study was to
describe the different organisation of diagnostics and treatment of IPF and ILD in the Nordic countries.
Methods: All university and regional hospitals with respiratory physicians were invited to respond to a
questionnaire collecting data on the number of physicians, nurses, patients with ILD/IPF, the presence of and
adherence to disease-specific national and international guidelines, diagnosis and treatment including ILD-
specific palliation and rehabilitation programmes.
Results: Twenty-four university and 22 regional hospitals returned the questionnaire. ILD and IPF incidence
varied between 1.4 and 20/100,000 and 0.4 and 10/100,000, respectively. Denmark and Estonia have official
national plans for the organisation of ILD. The majority of patients are managed at the university hospitals.
The regional hospitals each manage 46 (5200) patients with ILD and 10 (020) patients with IPF. There are
from one to four ILD centres in each country with a median of two ILD specialists employed. Specialised ILD
nurses are present in nine hospitals. None of the Nordic countries have national guidelines made by health
authorities. The respiratory societies in Sweden, Norway and Denmark have developed national guidelines.
All hospitals except two use the ATS/ERS/JRS/ALAT IPF guidelines from 2011. The limited number of ILD
specialists, ILD-specialised radiologists and pathologists and the low volume of ILD centres were perceived as
bottlenecks for implementation of guidelines. Twenty of the 24 university hospitals have multidisciplinary
conferences (MDCs). Pulmonologists and radiologists take part in all MDCs while pathologists only participate at
17 hospitals. Prescription of pirfenidone is performed by all university hospitals except in Estonia. Triple therapy
with steroid, azathioprine and N-acetylcysteine is not used. No hospitals have specific palliation programmes for
patients with ILD/IPF, but 36 hospitals have the possibility of referring patients for palliative care, mostly based on
existing oncology palliative care teams; seven hospitals have rehabilitation programmes for ILD.
Conclusion: There are obvious differences between the organisations of ILD patients in the Nordic countries.
We call for national plans that consider the challenge of cultural and geographical differences and suggest
the establishment of national reference centres and satellite collaborative hospitals to enable development of
common guidelines for diagnostics, therapy and palliation in this patient group.
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D
ifferences in the organisation of idiopathic
pulmonary fibrosis (IPF) and interstitial lung
diseases (ILDs) in the Nordic countries are not
well described. Diagnostic setups, treatment modalities
and follow-up may vary due to national, cultural and
epidemiological features.
During an ongoing Nordic collaboration and develop-
ment of a common Nordic registry for patients with IPF
and other ILDs, the differences between the six Nordic
countries have become obvious. Research in the area of
ILDs, especially in IPF, has been increasing in the recent
years, and so has the number and size of randomized
controlled trials (13). Unfortunately, many trials have
had a negative outcome, except for those studying the
drugs pirfenidone (4, 5) and nintedanib (6). Pirfenidone
was the first drug developed for IPF and is now used in
clinical practice in most EU countries (7). Nintedanib is
the second drug developed and will probably be available
during 2015.
A comparison of experiences from European centres
on adherence to pirfenidone has shown that more pa-
tients discontinue pirfenidone or continue treatment at a
reduced dose compared to results from the capacity (5)
randomized trials (personal communication). This obser-
vation is not uncommon when comparing randomized
trials to real-world settings. However, the need for high-
quality and highly specialised centres has become even
more evident in a rare disease like IPF with a very dismal
prognosis. Thus, there will be an increasing need for
ILD centres with high-quality diagnostic and treatment
services to diagnose, classify and treat patients with ILD
including IPF.
A PubMed search using the search terms: ‘ILD’, ‘inter-
stitial lung disease’, ‘IPF’, ‘idiopathic pulmonary fibrosis’,
‘organization’, ‘structure’, ‘service’, ‘care’ in different com-
binations resulted in one study from France (8). This
questionnaire-based survey showed that 20% of French
pulmonologists were involved in the management of IPF
patients. The survey showed that 36% of cases were dis-
cussed at a multidisciplinary conference (MDC). The 2011
international guidelines for IPF (9) were known by 67% of
the pulmonologists and 84% considered them appropriate
for clinical practice.
In other diseases such as asthma, existing data suggest
that a structured approach to care delivery has a positive
impact on outcomes at reduced costs (10). A systematic
approach to asthma management undertaken in Finland
has decreased morbidity, mortality and the associated
direct and indirect costs (11). In the UK, the Royal
College of Physicians has published a document, ‘Allergy
the Unmet Need’ (12), which describes the prevalence of
allergic diseases, as well as current services and training
needs pertaining to allergy care.
A robust organisation of IPF and ILD treatment
may facilitate earlier identification of patients as well as a
more confident diagnosis, and thus earlier initiation of
treatment. Furthermore, patients suited for participation
in clinical trials would be identified earlier. Well-organised
IPF programmes including specific nurse programmes
focus on the management of side effects, adherence to
treatment, palliation and advance care programmes will
improve ILD and IPF services and treatment and possibly
also the survival of this patient group.
This study was designed to establish a platform for a
similarly structured approach to IPF and ILD manage-
ment in the Nordic countries. The aim of the present
study was to describe the organisation of IPF and ILD in
the Nordic countries.
Methods
A national questionnaire (see Supplementary file 1) was filled
in by each author of this paper from each Nordic country
(Denmark, Estonia, Finland, Iceland, Norway and Sweden).
The data collected included the number of specialists in
respiratory medicine and the number of hospitals with
respiratory services and ILD centres in each country.
Data on epidemiology of IPF and ILD in each country
were included. In addition, questions on the existence
of organisational plans from national health authorities,
the existence of national, regional or local guidelines and
if present, how the guidelines were use are being complied
and a description of possible bottlenecks for their im-
plementation were included.
Another regional questionnaire (see Supplementary
file 2) was aimed at all other hospitals with a specialised
respiratory department. All Nordic university hospitals
(UHs) and most regional hospitals were invited to
participate. The regional questionnaire was sent out to
the respiratory physician in charge of ILD patients and in
case of a delayed answer followed up by reminders and in
some cases a telephone call. The second questionnaire
collected data on the presence of guidelines, adherence to
international guidelines in the field, number of physicians
and nurses and estimated numbers of ILD/IPF patients
in each centre, presence of specialised ILD nurses and
specific nursing guidelines, presence of ILD-specific pallia-
tion, advance care planning and rehabilitation programmes.
Moreover, data on diagnostic packages, presence and
organisation of MDCs, and treatment strategy on phar-
maceutical intervention and participation in clinical trials
were collected.
Data analysis was descriptive.
Results
All Nordic UHs participated: Iceland 1/1 UH, Estonia
2/2 UHs, Denmark 3/3 UHs, Finland 5/5 UHs, Norway
7/7 UHs and in Sweden 6/7 UHs responded to the
questionnaire (Fig. 1).
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Regional hospitals also participated in the questionnaire,
one from Norway, four from Sweden and 17 from Denmark.
The Nordic countries each have between one and four
ILD centres. The demographics are shown in Table 1.
Incidence of ILD/IPF
The incidence of ILD and IPF in the Nordic countries is
unknown. Data are based on estimates from retrospective
(Denmark) or prospective studies (Finland, Iceland), on
international prevalence rates (Sweden) or extrapolated
data from a single hospital (Norway). ILD incidence
varied between 1.4 and 20/100,000 and IPF incidence
between 0.4 and 10/100,000/year.
Overall organisation
Only two countries (Denmark and Estonia) have an
official national plan for the organisation of ILDs. In
Denmark, the Danish Health and Medicines Authority
recommends that diagnosis and treatment of all ILD,
except ‘simple’ IPF (‘simple’ is not defined), should be
managed by three highly specialised centres at the UHs.
At a meeting in the Danish Society of Respiratory
Fig. 1. Location of the Nordic University Hospitals (red dots).
Table 1. Number of inhabitants, hospitals and respiratory specialists in the Nordic countries
Denmark Estonia Finland Iceland Norway Sweden
Inhabitants (n) 5,650,000 1,315,819 5,474,094 0,326,340 5,109,059 9,694,194
University hospitals (n) 4 1 5 1 7 7
ILD centres (n) 3 2 0 1 3 4
Other hospitalsa (n) 11 9 28 0 17 35
Respiratory specialists (n) 130 99 200 16 180 400
Specialist/100,000 inhabitants 2.3 7.5 3.7 4.9 3.5 4.1
Inhabitants/resp. Physician 43,461 13,291 27,370 20,396 28,384 24,236
aRegional hospitals with departments of respiratory medicine.
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Medicine, it was agreed that pirfenidone prescriptions
should be restricted to those three centres. In Estonia, two
ILD centres, one located at the UH, informally manage
ILD/IPF patients. This agreement is stated in the National
Development Plan for Respiratory Diseases made by the
Estonian Respiratory Society for the Health Ministry.
Norway, Sweden, Finland and Iceland have no official
plans for diagnosis and management of ILD, but by
tradition, the majority of patients are managed at UHs
and larger regional hospitals. However, no complete data
exist on the number of patients with ILD and IPF being
managed at regional hospitals in the Nordic countries; in
Denmark, 17 regional hospitals manage approximately
46 (5200) ILD patients and 8 (020) IPF patients each.
In Sweden, the four regional hospitals managed 39 (666)
ILD and 13 (1020) IPF patients according to the
questionnaire responses.
Respiratory physicians
Estonia has 7.5 respiratory physicians per 100,000 in-
habitants while Denmark has only 2.3, corresponding to
13,291 and 43,461 inhabitants per respiratory specialist,
respectively. Finland, Iceland, Norway and Sweden have
from 3.5 to 4.9 respiratory physicians per 100,000 inhabi-
tants, corresponding to 20,39628,384 inhabitants per
specialist. There is a median of two ILD specialists per
centre in each Nordic country. Specialised ILD nurses
were present in nine hospitals and six of these had specific
guidelines for nurses to independently manage pirfeni-
done side effects.
Guidelines
None of the six Nordic countries have national guidelines
made by health authorities. The respiratory societies,
one in Sweden, Norway and Denmark, have developed
national guidelines. In Sweden, the guidelines for IPF and
for sarcoidosis are developed by experts appointed by the
Swedish Respiratory Society. In Norway, the guidelines
were written after a consensus meeting with participation
of respiratory specialists from the seven UHs. In Denmark,
a group of experts appointed by the Danish Society of
Respiratory Medicine made the guidelines. Finland has
a regional guideline in one region and a few hospitals
in Denmark and Finland also have local, hospital-based
guidelines for the diagnosis and management of ILD and
IPF. When the participants in the survey were asked to
identify the bottlenecks for implementation of IPF guide-
lines, they mentioned the limited number of ILD specia-
lists, ILD-specialised radiologists and pathologists and
the low volume of ILD centres as problems per se and as
a problem for organisation of routine MDCs. In some
countries, the large number of small hospital units mana-
ging only few ILD/IPF patients was seen as bottlenecks
for high-quality service.
All hospitals except two use the ATS/ERS/JRS/ALAT
IPF guidelines from 2011, while only 28 of 36 hospitals
use the ATS/ERS idiopathic interstitial pneumonias
guidelines from 2001.
Registries for ILD and IPF in the Nordic countries
Several ILD and IPF registries exist in the Nordic
countries. Finland and Sweden have started national
IPF registries in 2011 and 2014, respectively. Denmark,
Norway and Iceland have registries including all ILDs
except sarcoidosis, and a similar registry is planned in
Estonia. All the Nordic countries collaborate on a com-
mon Nordic IPF registry based on the existing national
registries.
Diagnostic strategies and multidisciplinary
discussions
The presence of a diagnostic package for newly referred
patients was confirmed by 50% (12/24) of the UHs, and
50% (12/22) of regional hospitals also used diagnostic
packages. A diagnostic package was defined as pre-
specified investigations, such as high resolution computed
tomography (HRCT), pulmonary function tests, 6-min
walk test, blood sampling, echocardiography, etc., ordered
routinely and not based on an individual patient assessment.
Twenty of the 24 UHs had regular MDCs; at five hos-
pitals MDCs had been introduced before 2010, while
the rest had started in recent years. Eight of the regional
hospitals had MDCs, in some cases as a part of a lung
cancer conference. In total, 28 of 46 hospitals had MDCs.
Pulmonologists (between one and six) and radiolo-
gists (between one and five) took part in all MDCs. In
17 hospitals, one pathologist participated in the MDCs
and in 11 hospitals, rheumatologists participated. Nurses,
clinical physiologists, thoracic surgeons, intensive care
physicians, coordinators, oncologists and infectious dis-
ease specialists participated in MDCs at a limited number
of hospitals.
Treatment
Prescription of pirfenidone was performed by all UHs
except in Estonia, where there is no reimbursement
available yet (pirfenidone is only accessible if the patients
can pay for the entire drug cost). All participating regional
hospitals in Sweden and Norway prescribed pirfenidone,
while none of the Danish regional hospitals did. There
were differences in how drugs were reimbursed. In Denmark,
the total costs are reimbursed by the health care system.
In the other Nordic countries, the patients have to pay
a minor part. In Norway, the physician has to apply
separately for drug reimbursement for each patient. In
Finland, pirfenidone can be prescribed by all physicians,
but the physician has to apply for reimbursement to each
patient, and patients pay an annual sum of t640 until
a higher reimbursement status is granted to the drug
(probably in 2015). In Iceland, only specialists in respira-
tory medicine can prescribe pirfenidone and in Denmark,
the prescription is limited to the ILD centres. None of the
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46 hospitals used triple therapy with steroid, azathioprin
and N-acetylcysteine. Ten hospitals, including three UHs,
used oral steroids as monotherapy. Before May 2014,
N-acetylcysteine was used as monotherapy in all Danish
UHs, 13/17 regional hospitals, 1/5 Finnish UHs, and 1/6
Norwegian UHs; in the UH in Iceland, in 2/6 Swedish
UHs and in 1/4 regional hospitals and in no hospitals
in Estonia. An interim analysis of the Panther trial (13)
resulted in cessation of N-acetylcysteine monotherapy
in most hospitals (personal communication). All Danish,
three Finnish, three Norwegian and two Swedish UHs
participated in pharmaceutical clinical trials.
Palliation and rehabilitation
None of the hospitals had developed specific palliative
care programmes or advance care planning specifically for
IPF patients. A single centre participated in a research
project on advance care planning. Almost all hospitals
(36/45) had the possibility of referring patients for pallia-
tive care, mostly based on existing oncology palliative care
teams. Two hospitals used oxygen nurse specialists with-
out specific palliative education and Norway and Estonia
used nursing homes. Most hospitals in Finland, Norway,
Sweden, Iceland and Estonia (17/21) could refer patients
for psychosocial support such as psychologists, hospital
priests and social workers, while only 4/20 hospitals in
Denmark had that option. Three Norwegian hospitals,
two Estonian, one Swedish and the university hospital in
Iceland had specific rehabilitation programmes for IPF
patients, while most other hospitals referred patients to
the rehabilitation programmes for chronic obstructive
pulmonary disease (COPD) either at the hospital or in
primary care settings. Ambulatory oxygen was prescribed
by 18/20 Danish hospitals, all Finnish UHs, one Norwegian,
all Estonian and Icelandic and 4/6 Swedish hospitals.
Indications varied widely reflecting the lack of evidence-
based guidelines (Table 2).
Discussion
ILDs comprise a heterogeneous group of inflammatory
and fibrotic lung diseases with variable treatment re-
sponses and prognosis. IPF is the most common of the
idiopathic interstitial pneumonias and is a chronic fibrotic,
irreversibly progressive ILD with an estimated incidence in
the Nordic countries of 0.410/100,000 corresponding
to 1980 new IPF patients each year in Iceland and
Sweden, respectively. The majority of general practitio-
ners will only meet 12 patients in their career and even
respiratory physicians may only encounter few patients
and thus have difficulties in achieving sufficient experience
in the diagnosis and treatment of this patient group.
Thus, the organisation of ILD and IPF care is important
to ensure high-quality care. Other rare diseases, such as
pulmonary arterial hypertension and cystic fibrosis, are
organised in a few national centres in many countries, but it
remains to be seen if a similar organisation can be
extrapolated to the field of ILD. The optimal organisation
is unknown. However, one or more national reference
centre with regional competence centres may be a solution
in medium- and large-sized countries, while a few reference
centres in smaller countries seem rational. In France, the
overall organisation is defined by a French national plan
for rare diseases, in which diagnostics and management of
IPF is coordinated between one national reference centre
and nine regional competence centres (8). From the present
Nordic questionnaire, it seems obvious that many Nordic
regional hospitals diagnose and manage a small number of
ILD and IPF patients. In a study from USA, it was shown
that delayed access to a tertiary centre was associated
with an increased risk of death independent of sex,
age, pulmonary function and educational level of patients
(14). Patient’s delay was 2.2 years (1.03.8 years) in
the USA (14), while Danish patients had a median
duration of 13 months from patient-reported symptoms
until the first visit to the referral centre (interquartile range
636 months) (15). Preliminary studies from the Finnish
IPF registry suggest that the disease is diagnosed at a
mild stage in Finland (16). Thus, early referral to an expert
centre seems justified in known or suspected ILD. More-
over, early referral, diagnosis and treatment evaluation
seem paramount in the light of the new treatment options
with the potential of slowing disease progression.
Even though the organisation of diagnosis and treat-
ment is heterogeneous with both ILD centres and smaller
hospitals managing ILD and IPF patients, all hospitals
are aware of and use the ATS/ERS/JRS/ALAT IPF guide-
lines from 2011 (9). Only three of the Nordic countries
have specific national guidelines, but some hospitals in
Denmark and Finland have national or local guidelines.
On the basis of this survey, the question remains whether
this is reflected in the number of patients treated with
antifibrotic drugs or in long-term survival. More than
half of the hospitals have a ‘diagnostic package’ with
pre-specified investigations that all patients go through.
Table 2. Different indications for ambulatory oxygen in
Nordic hospitals
Desaturation at 6-min walk test below 80%, 85%, 86%, 88%, or
more than 4%
Improved walking distance above 30 m, 53 m or unspecified
improvement
Dyspnea
Subjective improvement of dyspnea when walking with oxygen
Dizziness and headache
Reduced DLCO
Standard LTOT indication (paO2B7.3 kPa or 60 mmHg)
Being on lung transplantation waiting list
DLCOdiffusion capacity for carbon monoxide; LTOTlong-
term oxygen therapy.
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It remains to be seen if this leads to an earlier and faster
diagnosis, as it has been shown in patients with cancer. As
IPF has the same or even a worse prognosis compared with
many cancers, fast and timely diagnosis and treatment may
save valuable time and resources.
A multidisciplinary approach in the diagnosis of IPF
and other ILDs is recommended in the ATS/ERS state-
ment ‘Idiopathic pulmonary fibrosis: evidence-based
guidelines for diagnosis and management’ (9) and ‘Update
of the International Multidisciplinary Classification of
the Idiopathic Interstitial Pneumonias’ (17) as this has
been shown to improve diagnostic certainty. The optimal
composition of specialists in a MDC is unknown, but the
statements recommend that pulmonologists, radiologists
and pathologists participate. It is even recommended to
refer patients to centres with MDC if a MDC is not present
at their local hospital (9). Strikingly, not all UHs had
routine MDCs and in many centres, MDCs were started
only recently. According to the current survey, a respira-
tory physician and a radiologist participated in all MDCs,
while pathologists only participated in less than half.
A number of other specialists participated in the MDCs;
it remains to be seen if the participation of other specialists
will improve the diagnostic certainty.
Many hospitals refer patients with IPF to the rehabilita-
tion programmes for COPD since specific rehabilitation
programmes for patients with ILD and IPF do not exist.
Studies have shown that patients benefit from participating
in disease-specific rehabilitation programmes considering
the disease-specific physiology into account; the disease-
specific physiology in ILD is very different from that of
COPD (1820). Also, the patient education that normally
forms part of any COPD rehabilitation program obviously
needs to be tailored differently to meet the needs of
patients with IPF. The programmes must include informa-
tion on breathing patterns and exercises, specific IPF and
ILD therapy, palliation, advance care planning and end-
of-life decisions (18).
Palliative care programmes for IPF are sparse and the
patients’ needs probably differ from those of patients with
COPD and cancer (21, 22). Health care professionals
often struggle with finding solutions for patients with IPF
and recognize the difficulties of balancing information
needs with maintaining hope. On the other hand, non-ILD
professionals admit not to possess sufficient understand-
ing of or experience with the disease (23). Therefore,
a disease-specific organisation of IPF palliation is strongly
needed.
In conclusion, there are many unmet needs in the care
of patients with ILD and IPF. There is an obvious lack of
evidence for the optimal organisation of care, although
studies suggest that patients in highly specialised centres
have a better survival independent of disease stage, pulmo-
nary function and other parameters (24). Therefore, we
call for national plans that take into account the challenge
of cultural and geographical differences. We suggest the
development of national reference centres and satellite
collaborative hospitals. This strategy will enable the devel-
opment of common guidelines for diagnosis and therapy,
access to randomized controlled trials for all eligible
patients and a common strategy for palliation including
advance care planning and end-of-life decisions. Access to
high-quality health care for patients with ILD is needed to
improve quality of life and prognosis for these patients.
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